Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway. The gene discussed is APOA5; the disease is metabolic dysfunction-associated steatotic liver disease.